Evaluation of fracture risk and fracture prevention: An Italian picture

Clinical Cases in Mineral and Bone Metabolism

Volumn 9, Issue 2, 2012, Pages 73-75

  Brandi, Maria Luisa ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

BMD; Epidemiology; Fragility fractures; Italian Osteoporosis Committee

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BAZEDOXIFENE; CALCIUM; COLECALCIFEROL; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE TURNOVER; DRUG COST; DRUG MEGADOSE; FRACTURE; FRAGILITY FRACTURE; FRAIL ELDERLY; HIP FRACTURE; HUMAN; LIFE EXPECTANCY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RISK ASSESSMENT; SHORT SURVEY; SPINE FRACTURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 84867356349     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (32)

1. Italian Statistics 2008. National Institute of Statistics, Rome, 2009.
2. Piscitelli P, Guida G, Iolascon G, et al. Incidence and costs of hip fractures vs. acute myocardial infarction in the Italian population: a 4 years survey. Osteoporos Int 2007;18:211-219. (Pubitemid 46090225)
3. Adami S, Giannini S, Giorgino R, et al. The effect of age, weight, and lifestyle factors on calcaneal quantitative ultrasound: the ESOPO study. Osteoporos Int 2003;14:198-207. (Pubitemid 40826232)
4. Piscitelli P, Brandi ML, Chitano G, et al. Epidemiology of fragility fractures in Italy. Clin Cases Miner Bone Metab 2011;8:29-34.
5. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 Suppl):505S-511S.
6. Piscitelli P, Gimigliano F, Gatto S, et al. Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int 2010; 21:1223-1230.
7. Tarantino U, Piscitelli P, Brandi ML, et al. The incidence of hip, forearm, humeral, ankle and vertebral fragility fractures in Italy: Results from a 3-years multicentric study. Arthr Res Ther 2010;12:R226.
8. Husserius R, Karlsson MK, Nilsson BE, et al. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a ten-year population-based study in 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003;14:61-68. (Pubitemid 36267902)
9. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fractures in the year following a fracture. JAMA 2001;285:320-323. (Pubitemid 32095035)
10. Pongchaiyakul C, Nguyen ND, Jones G, et al. Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res 2005;20:1349-1355. (Pubitemid 41033519)
11. Ismail AA, O'Neill TW, Cooper C, et al. Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 1998;8:291-297. (Pubitemid 28427080)
12. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739. (Pubitemid 30174026)
13. Clinton J. Proximal humeral fracture as a risk factor for subsequent hip fractures. J Bone Joint Surg 2009;91:503-511.
14. Vochteloo AJ, Borger van der Burg BL, Roling MA, et al. Contralateral hip fractures and other osteoporosis-related fractures in hip fracture patients: Incidence and risk factors. An observational cohort study of 1,299 patients. Arch Orthop Trauma Surg 2012;132:1191-1197.
15. Piscitelli P, Chitano G, Johansson H, et al. Updated fracture incidence rates for the Italian version of FRAX. Osteoporos Int 2012; in press.
16. Piscitelli P, Parri S, Brandi ML. Antifracture drugs consumption in Tuscany Region before the TARGeT project: A valuable model for the analysis of administrative databases. Clin Cases Miner Bone Metab 2012; in press.
17. Body JJ, Bergmann P, Boonen S, et al. Non-pharmacological management of osteoporosis: A consensus of the Belgian Bone Club. Osteoporos Int 2011;22:2769-2788.
18. Bischoff-Ferari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367:40-49.
19. Rabenda V, Bruyére O, Reginster J-Y. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: A meta-regression. Osteoporos Int 2011;22:893-901.
20. Peris P, Marttinez-Ferrer A, Monegal A, et al. 25 hydroxyvitamin D serum levels influence adeguate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 2012;51:54-58.
21. Reginster J-Y. Antifracture efficacy of currently availablke therapies for postmenopausal oseoporosis. Drugs 2011;71:65-78.
22. Rizzoli R, Reginster J-Y, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011;89: 91-104.
23. Hiligsmann M, Boonen A, Rabenda V, Reginster J-Y. The importance of integrating medication adherence into pharmacoeconomic analyses: The example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2012;12:159-166.
24. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008;23:1569-1575.
25. Kanis JA, Reginster J-Y, Kaufman JM, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 2012;23:213-221.
26. Giangregorio L, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: An international phenomenon. Sem Arthritis Rheum 2006;35:293-305.
27. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: A systematic review. Osteoporos Int 2004;15:767-778. (Pubitemid 39361946)
28. Papaioannou A, Giangregorio L, Kvern B, et al. The osteoporosis care gap in Canada. BMC Musculoskel Disorders 2004;5:11.
29. Ciaschini PM, Straus SE, Dolovich LR, et al. Community based intervention to optimize osteoporosis management: Randomized controlled trial. BMC Geriatrics 2010;10:60-66.
30. Jansen JP, Gaugris S, Bergman G, Sen SS. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Curr Med Res Opin 2008;24:671-684. (Pubitemid 351428978)
31. Ralston SH, Binkley N, Boonen S, et al. Randomized trial of alendronate plus vitamin D versus standard of care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int 2011;88:485-494.
32. Piscitelli P, Marcucci G, Parri S, et al. Compliance to antifracture treatments in Tuscany: A regional survey based on institutional pharmaceutical dataset. Clin Cases Miner Bone Metab 2011;8:62-65.